1325279--4/15/2010--CELLCYTE_GENETICS

related topics

{product, candidate, development}

{operation, natural, condition}

{interest, director, officer}

{property, intellectual, protect}

{control, financial, internal}

{cost, regulation, environmental}

{stock, price, share}

{personnel, key, retain}

{acquisition, growth, future}

{customer, product, revenue}

{regulation, government, change}

{financial, litigation, operation}

An investment in our common stock involves a number of significant risks. You should carefully consider the following risks and uncertainties in addition to other information in this Annual Report in evaluating our company. Our business, operating results and financial condition could be seriously harmed due to any of these risks. The risks described below are not all of the risks facing our company. Additional risks not presently known to us or that we currently consider immaterial may also impair our business operations. You may lose all or part of your investment due to any of these risks. Our financial situation is precarious and, based on currently estimated operating expenses, our existing capital resources will not be sufficient to fund our operations beyond the next three months. Our independent registered public accounting firm s report states that there is a substantial doubt that we will be able to continue as a going concern. We may need but fail to obtain partners to support our development efforts and to commercialize our technology. We may not be awarded any State or federal research grants. We have a history of operating losses, and we may fail to obtain revenues or become profitable. If we are unable to protect our patents and proprietary rights, our business, financial condition and results of operations will be harmed. If we are unable to obtain necessary licenses to third-party patents and other rights, we may not be able to commercially develop our expected products. We compete with companies that have significant advantages over us. We are dependent on the services of key consultants and contractors. Our activities involve hazardous materials; improper handling of these materials by our employees, contractors or agents could expose us to significant legal and financial penalties. We have been subject to legal proceedings. We are dependent upon third-party suppliers for raw materials needed for the manufacture of our products. If any of these third parties fail or are unable to perform in a timely manner, our ability to manufacture and deliver will be compromised. We have limited liquidity and capital resources and may not obtain the significant capital resources we will need to sustain our research and development efforts. Our stock price will likely be highly volatile, which may negatively affect our ability to obtain additional financing in the future.

Full 10-K form ▸

1325279--4/15/2010--CELLCYTE_GENETICS_CORP